Bayesian approach for pediatric trials in MS. We need more flexibility for future MS trial design, especially for children. #bayesian #MultipleSclerosis jamanetwork.com/journals/jaman…

Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network dlvr.it/SZ8zhJ

Our new recent paper on long-term EDSS disability trajectories in patients with Secondary progressive Multiple Sclerosis. Great result with the Big MS Data Network. lnkd.in/dv-6mHMM #BigMS #Latentclass #Longterm #Disability #Secondaryprogressive

Today at #ECTRIMS2022 with the poster on emulation of a clinical trial using real-world data from MSBase Registry. ECTRIMS

Very interesting scientific approach presented by @ Maria Pia Sormani at #ECTRIMS2022

This implies that "the" hazard ratio from a Cox model is actually a weighted average of the time-varying hazard ratios over follow-up. So "the" hazard ratio isn't comparable between studies with different follow-up length or censoring pattern. Let's use adjusted absolute risks.

Another superb piece of evidence by the Meet-URO team revealing #meeturo score as more contemporary prognostic classification system for patients with metastatic #renalcancer treated with first-line combo #immunotherapy OncoAlert OncoViews authors.elsevier.com/sd/article/S20…

The use of #AHSCT in people with active #SPMS is associated with a slowing of disability progression and a higher likelihood of disability improvement compared to standard immunotherapy. An Italian study from the BMT-MS Study group and the MS Register. n.neurology.org/content/early/…

GRASP | Glossario Ragionato, Approfondimenti, Strumentario Pratico grasp.accmed.org STRUMENTARIO PRATICO | 19.01.2023 Dalle tabelle di contingenza alla regressione logistica A cura di Alessio Signori, Genova Alessio Signori ow.ly/SV6150ME9mS

A well-organized course on all methodological issues of clinical trials and observational studies. It was a great pleasure to be invited to give my contribution.

Our last network meta-analysis on efficacy of innovative therapies for #myasteniagravis. francesco saccà European Academy of Neurology doi.org/10.1111/ene.15…

Although confounding bias resulting from the lack of randomisation cannot be eliminated, our recent findings suggest that rigorous #target #trial #emulation could provide informative results for comparative #effectiveness research. jnnp.bmj.com/content/early/…

Randomized clinical trials in progressive #MultipleSclerosis often revealed non-significant effects on disability progression, unless we assume a therapeutic lag. Re-analysis of SPECTRIMS and PROMISE studies from Noemi Montobbio Università di Genova ▶️ journals.sagepub.com/doi/10.1177/13…

Oggi seconda giornata di lavori per i partecipanti alla II^ Edizione della Meet-URO Academy. Workshop di Comunicazione, con i Dr. Tozzi e Dr. Geusaldo, Workshop di impostazione di studio osservazionale guidati dal Prof. Signori. Grazie a tutti per la partecipazione

Race and ethnicity in multiple sclerosis phase 3 clinical trials. The last review on social determinants of health in MS patients recruited in phase 3 clinical trials. journals.sagepub.com/doi/10.1177/13…

Check out our new R package for highly customisable and reproducible analysis of disability progression in multiple sclerosis: github.com/noemimontobbio…

A first exciting day at the 40th ECTRIMS with all my colleagues

New paper out now ANA Journals - Exploring the evolution of relapse-associated and relapse independent disability worsening in #MultipleSclerosis over different treatment eras: doi.org/10.1002/ana.27…

In this work we presented an alternative method for quantifying treatment effects when using time-to-event endpoints. Specifically, restricted mean survival time (RMST) was applied to two RCTs in patients with progressive multiple sclerosis. jamanetwork.com/journals/jaman…

La 3° edizione dell’ #internationalclinicalresearchcourse di #AIOM/ASCO è un successo in termini di partecipazione, condivisione e crescita. Un’opportunità d’incontro tra #oncologi di tutto il mondo che hanno potuto confrontarsi su temi innovativi a tutto vantaggio dei #pazienti.